Market Overview

UPDATE: Jefferies Initiates AbbVie at Buy on Growth Outlook, High Yield

Related ABBV
Glaxo's Tanzeum Approved in the U.S. - Analyst Blog
Abbott Labs Tops Earnings, Misses Sales Est - Analyst Blog

Jefferies initiated coverage on AbbVie (NYSE: ABBV) with a Buy rating and a $44.00 price target.

Jefferies commented, "AbbVie is our top pick for 2013. We see the initial trading volatility post-spin as an opportune entry point into the shares as we soon expect income funds to work the dividend yield down to at least the 4.0% level. A more durable long-term performance from Humira, stronger pipeline delivery and operating margin expansion drive our cash EPS estimates up to 22% ahead of consensus."

AbbVie closed at $34.09 on Tuesday.

Posted-In: JefferiesAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Most Popular

Related Articles (ABBV)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free